Efficacy of Secondary Prophylaxis with Vancomycin for Preventing Recurrent Clostridium difficile Infections

American Journal of Gastroenterology

Volumn 111, Issue 12, 2016, Pages 1834-1840

  Carignan, Alex ^a   Poulin, Sébastien ^a   Martin, Philippe ^a   Labbé, Annie Claude ^b   Valiquette, Louis ^a   Al Bachari, Hamed ^b   Montpetit, Louis Philippe ^a   Pépin, Jacques ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; METRONIDAZOLE; QUINOLONE DERIVATIVE; UREIDOPENICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUEBEC; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; TERTIARY CARE CENTER; TREATMENT DURATION; ADOLESCENT; AGE; CASE CONTROL STUDY; CLOSTRIDIUM INFECTION; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUEBEC; RECURRENCE; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; VANCOMYCIN; YOUNG ADULT;

EID: 84987643673     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.417     Document Type: Article

References (33)

1. Pepin J, Valiquette L, Alary M-E et al. C lostridium diffi cile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72.
2. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium diffi cile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
3. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium diffi cile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
4. Marsh JW, Arora R, Schlackman JL et al. Association of relapse of Clostridium diffi cile disease with BI/NAP1/027. J Clin Microbiol 2012; 50: 4078-82.
5. Petrella LA, Sambol SP, Cheknis A et al. Decreased cure and increased recurrence rates for Clostridium diffi cile infection caused by the epidemic C. diffi cile BI strain. Clin Infect Dis 2012; 55: 351-7.
6. Musher DM, Aslam S, Logan N et al. Relatively poor outcome aft er treatment of Clostridium diffi cile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-90.
7. Pepin J, Alary M-E, Valiquette L et al. Increasing risk of relapse aft er treatment of Clostridium diffi cile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-7.
8. Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium diffi cile infection (CDI). Vaccine 2010; 28: 965-9.
9. Hu MY, Katchar K, Kyne L et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium diffi cile infection. Gastroenterology 2009; 136: 1206-14.
10. Abou Chakra CN, Pepin J, Sirard S et al. Risk factors for recurrence, complications and mortality in Clostridium diffi cile infection: a systematic review. PLoS One 2014; 9: e98400.
11. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium diffi cile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
12. Shin JW, Yong D, Kim MS et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother 2003; 9: 62-7; discussion 104-105.
13. Miller M, Bernard L, Th ompson M et al. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium diffi cile infection. Infect Control Hosp Epidemiol 2010; 31: 710-5.
14. Kyne L, Warny M, Qamar A et al. Association between antibody response to toxin A and protection against recurrent Clostridium diffi cile diarrhoea. Lancet 2001; 357: 189-93.
15. Garey KW, Jiang Z-D, Ghantoji S et al. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium diffi cile infection. Clin Infect Dis 2010; 51: 1406-10.
16. Freeman J, Baines SD, Saxton K et al. Eff ect of metronidazole on growth and toxin production by epidemic Clostridium diffi cile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
17. Garey KW, Sethi S, Yadav Y et al. Meta-analysis to assess risk factors for recurrent Clostridium diffi cile infection. J Hosp Infect 2008; 70: 298-304.
18. Eyre DW, Walker AS, Wyllie D et al. Predictors of fi rst recurrence of Clostridium diffi cile infection: implications for initial management. Clin Infect Dis 2012; 55 Suppl 2: S77-87.
19. Bassaris HP, Lianou PE, Legakis NJ et al. Interaction between Clostridium diffi cile and polymorphonuclear leucocytes from the elderly and postoperative cancer patients: phagocytosis and bactericidal function. Med Microbiol Immunol 1984; 173: 49-55.
20. Nakamura S, Mikawa M, Nakashio S et al. Isolation of Clostridium diffi cile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 1981; 25: 345-51.
21. Bacon AE, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium diffi cile in the general population and patients with antibioticassociated diarrhea. Diagn Microbiol Infect Dis 1994; 18: 205-9.
22. Viscidi R, Laughon BE, Yolken R et al. Serum antibody response to toxins A and B of Clostridium diffi cile. J Infect Dis 1983; 148: 93-100.
23. Surawicz CM. Reining in recurrent. YGAST 2009; 136: 1152-4.
24. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium diffi cile. N Engl J Med 2013; 368: 407-15.
25. Louie TJ, kKris C, H O et al. Fecal microbiome transplantation via oral fecal microbial capsules for recurrent Clostridium diffi cile infection. IDWeek 2013; 2013.
26. Baines SD, O'Connor R, Saxton K et al. Activity of vancomycin against epidemic Clostridium diffi cile strains in a human gut model. J Antimicrob Chemother 2009; 63: 520-5.
27. Gonzales M, Pepin J, Frost EH et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium diffi cile infection. BMC Infect Dis 2010; 10: 363.
28. Louie TJ, kKris C, Byrne B et al. Fidaxomicin preserves the intestinal micro biome during and aft er treatment of Clostridium diffi cile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 Suppl 2: S132-42.
29. Babakhani F, Bouillaut L, Gomez A et al. Fidaxomicin inhibits spore production in Clostridium diffi cile. Clin Infect Dis 2012; 55 Suppl 2: S162-69.
30. Finegold SM, Molitoris D, Vaisanen M-L et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004; 48: 4898-902.
31. Mullane KM, Miller MA, Weiss K et al. Effi cacy of fi daxomicin versus vancomycin as therapy for Clostridium diffi cile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53: 440-7.
32. Safety and Effi cacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Diffi cile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (Internet). (cited 11 March 2015) Available from https://www.clinicaltrials.gov/ct2/show/NCT01691248term= clostridium+diffi cile+AND+prophylaxis&rank=2.
33. Van Hise NW, Bryant AM, Hennessey EK et al. Effi cacy of oral vancomycin in preventing recurrent clostridium diffi cile infection in patients treated with systemic antimicrobial agents. Clin Infect Dis 2016; 63: 651-3.